Adding Pembrolizumab To Preoperative Radiotherapy and Surgery Improves DFS for Patients with Stage III Soft Tissue Sarcomas of the Extremity By Ogkologos - December 2, 2024 624 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SU2C-SARC032 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and... June 5, 2023 Plant-Based Diets and a New Treatment Combination for Prostate Cancer: Research... February 16, 2023 When Ellen Found Out There Was A Grieving Mother In The... March 12, 2019 Crazy Bride Called Off Her Wedding Because Her Guests Refused To... April 22, 2019 Load more HOT NEWS FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute... Breast Cancer Centers Rarely Follow National Screening Recommendations, Study Says NCI Initiative Aims to Boost CAR T-Cell Therapy Clinical Trials
